American Journal of Obstetrics & Gynecology
Volume 203, Issue 1 , Pages 52.e1-52.e6 , July 2010

Maternal use of bupropion and risk for congenital heart defects

Presented at the 49th Annual Meeting of the Teratology Society in Rio Grande, Puerto Rico, June 27-July 1, 2009, and at the 25th International Conference of Pharmacoepidemiology and Therapeutic Risk Management in Providence, Rhode Island, August 16-19, 2009.

  • Sura Alwan, MSc

      Affiliations

    • Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada
    • ,
  • Jennita Reefhuis, PhD

      Affiliations

    • National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA
    • Corresponding Author InformationReprints: Jennita Reefhuis, PhD, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, 1600 Clifton Rd., MS E-86, Atlanta, GA 30333
    • ,
  • Lorenzo D. Botto, MD

      Affiliations

    • Division of Medical Genetics, Department of Pediatrics, University of Utah, Salt Lake City, UT
    • ,
  • Sonja A. Rasmussen, MD, MS

      Affiliations

    • National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA
    • ,
  • Adolfo Correa, MD, MPH

      Affiliations

    • National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA
    • ,
  • Jan M. Friedman, MD, PhD

      Affiliations

    • Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada
    • ,
  • National Birth Defects Prevention Study

Received 9 October 2009 ,Revised 10 December 2009 ,Accepted 8 February 2010.

References 

  1. Ascher JA, Cole JO, Colin JN, et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry. 1995;56:395–401
  2. Hurt RD, Sachs DP, Glover ED, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med. 1997;337:1195–1202
  3. Wisner KL, Gelenberg AJ, Leonard H, Zarin D, Frank E. Pharmacologic treatment of depression during pregnancy. JAMA. 1999;282:1264–1269
  4. Tong VT, England LJ, Dietz PM, Asare LA. Smoking patterns and use of cessation interventions during pregnancy. Am J Prev Med. 2008;35:327–333
  5. Coleman T. Recommendations for the use of pharmacological smoking cessation strategies in pregnant women. CNS Drugs. 2007;21:983–993
  6. GlaxoSmithKline Bupropion Pregnancy Registry. Final report: 1 September 1997 through 31 March 2008. Registry Report. Wilmington, NC, 2008.
  7. Bupropion (amfebutamone): caution during pregnancy. Prescrire Int. 2005;14:225
  8. Cole JA, Modell JG, Haight BR, Cosmatos IS, Stoler JM, Walker AM. Bupropion in pregnancy and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf. 2007;16:474–484
  9. Yoon PW, Rasmussen SA, Lynberg MC, et al. The National Birth Defects Prevention Study. Public Health Rep. 2001;116(suppl):32–40
  10. Botto LD, Lin AE, Riehle-Colarusso T, Malik S, Correa A. National Birth Defects Prevention Study (Seeking causes: classifying and evaluating congenital heart defects in etiologic studies). Birth Defects Res A Clin Mol Teratol. 2007;79:714–727
  11. Waller DK, Shaw GM, Rasmussen SA, et al. National Birth Defects Prevention Study (Prepregnancy obesity as a risk factor for structural birth defects). Arch Pediatr Adolesc Med. 2007;161:745–750
  12. Frieden IJ, Reese V, Cohen D. PHACE syndrome: the association of posterior fossa brain malformations, hemangiomas, arterial anomalies, coarctation of the aorta and cardiac defects, and eye abnormalities. Arch Dermatol. 1996;132:307–311
  13. Alwan S, Reefhuis J, Rasmussen SA, Olney RS, Friedman JM. National Birth Defects Prevention Study (Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects). N Engl J Med. 2007;256:2684–2692
  14. Reller MD, Strickland MJ, Riehle-Colarusso T, Mahle WT, Correa A. Prevalence of congenital heart defects in metropolitan Atlanta, 1998-2005. J Pediatr. 2008;153:807–813
  15. Lewin MB, McBride KL, Pignatelli R, et al. Echocardiographic evaluation of asymptomatic parental and sibling cardiovascular anomalies associated with congenital left ventricular outflow tract lesions. Pediatrics. 2004;114:691–696
  16. Chun-Fai-Chan B, Koren G, Fayez I, et al. Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study. Am J Obstet Gynecol. 2005;192:932–936
  17. Tucker WE. Preclinical toxicology of bupropion: an overview. J Clin Psychiatry. 1983;44:60–62
  18. Diav-Citrin O, Shechtman S, Weinbaum D, et al. Paroxetine and fluoxetine in pregnancy: a prospective, multicenter, controlled, observational study. Br J Clin Pharmacol. 2008;66:695–705
  19. Louik C, Lin AE, Werler MM, Hernández-Díaz S, Mitchell AA. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med. 2007;356:2675–2683
  20. Källén BA, Otterblad Olausson P. Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A Clin Mol Teratol. 2007;79:301–308
  21. Berard A, Ramos E, Rey E, Blais L, St-Andre M, Oraichi D. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol. 2007;80:18–27
  22. Cole JA, Ephross SA, Cosmatos IS, Walker AM. Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf. 2007;16:1075–1085
  23. Wogelius P, Norgaard M, Gislum M, et al. Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations. Epidemiology. 2006;17:701–704

 Cite this article as: Alwan S, Reefhuis J, Botto LD, et al. Maternal use of bupropion and risk for congenital heart defects. Am J Obstet Gynecol 2010;203:52.e1-6.

 The National Birth Defects Prevention Study is funded by the Centers for Disease Control and Prevention.

 The findings and conclusions in this article are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

PII: S0002-9378(10)00220-6

doi: 10.1016/j.ajog.2010.02.015

American Journal of Obstetrics & Gynecology
Volume 203, Issue 1 , Pages 52.e1-52.e6 , July 2010

Article Tools